Table 2 Baseline characteristics after IPT weighting among patients with heart failure with preserved ejection fraction
| Â | SGLT2i versus DPP4i | SDb | SGLT2i versus GLP-1RA | SDb | ||
|---|---|---|---|---|---|---|
SGLT2i | DPP4i | SGLT2i | GLP-1RA | |||
(n = 2846) | (n = 2846)a | (n = 3578) | (n = 3578)a | |||
Sociodemographics | ||||||
 Age, mean (SD) | 75.7 (10.1) | 76.0 (11.0) | 2.0 | 71.3 (10.9) | 71.4 (10.5) | 0.6 |
 Male | 1030 (36.9) | 1069 (37.4) | 0.9 | 1489 (41.4) | 1487 (41.6) | 0.5 |
 Race, White | 2039 (73.2) | 2108 (73.7) | 1.2 | 2692 (74.8) | 2667 (74.7) | 0.4 |
 Race, Black | 403 (14.5) | 396 (13.8) | 1.8 | 461 (12.8) | 459 (12.8) | 0.1 |
 Other Race | 345 (12.4) | 356 (12.5) | 0.3 | 445 (12.4) | 446 (12.5) | 0.4 |
 Calendar year (2013, 2014, 2015) | 894 (32.1) | 939 (32.8) | 1.6 | 696 (19.4) | 669 (18.7) | 1.6 |
 Calendar year (2016, 2017) | 871 (31.2) | 896 (31.3) | 0.2 | 1089 (30.3) | 1082 (30.3) | 0.1 |
 Calendar year (2018, 2019) | 1023 (36.7) | 1026 (35.9) | 1.7 | 1813 (50.4) | 1820 (51.0) | 1.2 |
Diabetes-related factors | ||||||
 Metformin | 1375 (49.3) | 1378 (48.2) | 2.3 | 1735 (48.2) | 1714 (48.0) | 0.4 |
 Sulfonylureas | 1094 (39.2) | 1119 (39.1) | 0.2 | 1356 (37.7) | 1328 (37.2) | 1.0 |
 DPP4i |  |  |  | 1033 (28.7) | 1028 (28.8) | 0.2 |
 GLP-1RA | 154 (5.5) | 160 (5.6) | 0.3 |  |  |  |
 Insulin | 998 (35.8) | 1026 (35.9) | 0.2 | 2034 (56.5) | 2003 (56.1) | 0.9 |
 Thiazolidinediones | 161 (5.8) | 165 (5.8) | 0.1 | 217 (6.0) | 212 (5.9) | 0.3 |
 Diabetes, ocular complications | 433 (15.5) | 447 (15.6) | 0.3 | 736 (20.5) | 743 (20.8) | 0.8 |
 Diabetes, renal complications | 1144 (41.0) | 1164 (40.7) | 0.7 | 1605 (44.6) | 1608 (45.0) | 0.8 |
 Diabetes, neurological complications | 1209 (43.4) | 1197 (41.9) | 3.1 | 1851 (51.4) | 1824 (51.1) | 0.7 |
Cardiovascular factors | ||||||
 Frailty status | 800 (28.7) | 777 (27.1) | 3.4 | 683 (19.0) | 676 (18.9) | 0.1 |
 Myocardial infarction | 216 (7.8) | 241 (8.4) | 2.4 | 202 (5.6) | 210 (5.9) | 1.1 |
 Stroke | 54 (1.9) | 59 (2.1) | 0.9 | 53 (1.5) | 56 (1.6) | 0.8 |
 Peripheral vascular disease | 995 (35.7) | 972 (34.0) | 3.6 | 1103 (30.6) | 1103 (30.9) | 0.5 |
 Other ischemic heart disease | 1905 (68.3) | 1985 (69.4) | 2.3 | 2410 (67.0) | 2422 (67.8) | 1.8 |
 Renal insufficiency | 1753 (62.9) | 1785 (62.4) | 1.0 | 2052 (57.0) | 2052 (57.5) | 0.9 |
 ACE inhibitors | 1101 (39.5) | 1103 (38.6) | 1.9 | 1424 (39.6) | 1400 (39.2) | 0.8 |
 ARBs | 754 (27.0) | 821 (28.7) | 3.7 | 1107 (30.8) | 1088 (30.5) | 0.6 |
 Beta blockers | 2181 (78.3) | 2249 (78.6) | 1.0 | 2759 (76.7) | 2763 (77.3) | 1.6 |
 Calcium channel blockers | 1040 (37.3) | 1097 (38.3) | 2.1 | 1269 (35.3) | 1268 (35.5) | 0.5 |
 Non-dihydropyridine CCB | 488 (17.5) | 482 (16.9) | 1.7 | 510 (14.2) | 507 (14.2) | 0.0 |
 Thiazide diuretics | 701 (25.2) | 694 (24.3) | 2.0 | 930 (25.8) | 916 (25.6) | 0.5 |
 Loop diuretics | 2351 (84.3) | 2386 (83.4) | 2.5 | 3017 (83.8) | 2994 (83.8) | 0.0 |
 Aldosterone antagonists | 550 (19.7) | 562 (19.7) | 0.1 | 787 (21.9) | 773 (21.6) | 0.6 |
 Digoxin | 315 (11.3) | 335 (11.7) | 1.2 | 309 (8.6) | 313 (8.8) | 0.6 |
 Hydralazine/isosorbide | 764 (27.4) | 800 (28.0) | 1.3 | 928 (25.8) | 939 (26.3) | 1.1 |
 Other HF medicationsc | 24 (0.8) | 25 (0.9) | 0.4 | 51 (1.4) | 51 (1.4) | 0.0 |
 Statins | 2065 (74.1) | 2166 (75.7) | 3.7 | 2869 (79.7) | 2855 (79.9) | 0.5 |
 Anticoagulants | 1187 (42.6) | 1170 (40.9) | 3.4 | 1402 (38.9) | 1408 (39.4) | 1.0 |
 Antiplatelets | 695 (24.9) | 715 (25.0) | 0.1 | 921 (25.6) | 924 (25.9) | 0.6 |